PRINCETON, N.J., June 2 /PRNewswire/ -- IntegriChain, Inc. today announced the appointment of industry veteran John Bailye to the Company's Board of Directors, further bolstering its position as a leader in the pharmaceutical information services industry.
Mr. Bailye, 54, recently retired from his position as Chairman & CEO of Dendrite International after Dendrite was acquired by French information provider Cegedim. Under Mr. Bailye's leadership, Dendrite, a pharmaceutical sales force automation system company, grew to more than 3500 employees, acquired 23 companies and generated $450 million in global sales revenue to become the leading SFA tool in the pharmaceutical industry. Throughout his career, Mr. Bailye has served on a number of not-for-profit organizations, including the New Jersey Technology Council where he was co-Founder and Board Member. Currently, Mr. Bailye is also a director, advisor and investor in Solar Centre LLC, a General Partner of the Roxiticus Life Sciences Fund.
Kevin Leininger, Chief Executive Officer of IntegriChain commented, "We are thrilled to have John join our Board of Directors. John is a seasoned executive and leader who brings a wealth of experience and proven track record in building a strong information services company in the pharmaceutical industry."
"IntegriChain has an innovative approach to helping pharmaceutical companies take more advantage of their channel data for commercial applications such as forecasting, demand validation and product launch," said Mr. Bailye. "I am excited by the sizeable potential IntegriChain represents and I look forward to leveraging my experience to help the Company expand its possibilities even further."
About IntegriChain
IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and increase patient safety by maximizing transparency and accountability in the supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, sales forecasting, and demand analysis.
CONTACT: Jeffrey C. Sager, Vice President, Sales & Marketing of
IntegriChain, Inc., +1-609-806-5005, sales@integrichain.com
Web site: http://www.integrichain.com/
